Chronic prostatitis: Management strategies

Drugs

Volumn 69, Issue 1, 2009, Pages 71-84

  Murphy, Adam B ^a   Macejko, Amanda ^a   Taylor, Aisha ^a   Nadler, Robert B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; CERNITIN; CN 009; COTRIMOXAZOLE; DOXAZOSIN; FINASTERIDE; GABAPENTIN; GLYCOSAMINOGLYCAN; IBUPROFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOFLOXACIN; NARCOTIC AGENT; OPIATE; PENTOSAN POLYSULFATE; PLACEBO; PREGABALIN; QUERCETIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROFECOXIB; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; THIOCOLCHICOSIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST;

ALGORITHM; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; BLADDER CATHETERIZATION; CHRONIC PROSTATITIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG MEGADOSE; EJACULATION; FEEDBACK SYSTEM; HUMAN; INCIDENCE; MALE; MALE INFERTILITY; MEARES STAMEY 4 GLASS TEST; MINIMALLY INVASIVE SURGERY; MONOTHERAPY; NATIONAL HEALTH ORGANIZATION; PATHOPHYSIOLOGY; PELVIS FLOOR; PELVIS PAIN SYNDROME; PHARMACIST; PHYTOTHERAPY; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SABAL; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE CULTURE;

ADRENERGIC ALPHA-ANTAGONISTS; ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOFEEDBACK (PSYCHOLOGY); CHRONIC DISEASE; HUMANS; MALE; PHARMACISTS; PROFESSIONAL ROLE; PROSTATITIS; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

BACTERIA (MICROORGANISMS); SERENOA REPENS;

EID: 59749100421     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969010-00005     Document Type: Review

References (81)

1. Collins MM, Stafford RS, O'Leary MP, et al. How common is prostatitis? A national survey of physician visits. J Urol 1998 Apr; 159 (4): 1224-8
2. Nickel JC, Downey J, Hunter D, et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001 Mar; 165 (3): 842-5
3. Roberts RO, Jacobson DJ, Girman CJ, et al. Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol 2002 Dec; 168 (6): 2467-71
4. Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002 Mar; 167 (3): 1363-6
5. Calhoun EA, McNaughton Collins M, Pontari MA, et al. The economic impact of chronic prostatitis. Arch Intern Med 2004 Jun 14; 164 (11): 1231-6
6. Schaeffer AJ. Clinical practice: chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006 Oct 19; 355 (16): 1690-8
7. Litwin MS, McNaughton-Collins M, Fowler Jr FJ, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999 Aug; 162 (2): 369-75
8. Litwin MS. A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology 2002 Dec; 60 (6 Suppl.): 14-8; discussion 8-9
9. Schneider H, Wilbrandt K, Ludwig M, et al. Prostate-related pain in patients with chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2005 Feb; 95 (2): 238-43
10. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999 Jul 21; 282 (3): 236-7
11. de la Rosette JJ, Hubregtse MR, Meuleman EJ, et al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993 Apr; 41 (4): 301-7
12. Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/ chronic pelvic pain syndrome. Annu Rev Med 2006; 57:195-206
13. Nickel JC. The prostatitis manual: a practical guide to management of prostatitis/chronic pelvic pain syndrome. San Francisco (CA): Bladon Medical Publishing, 2002
14. Nickel J. Chronic prostatitis: current concepts and antimicrobial therapy. Infect Urol 2000; 13 (5a):s22-8
15. Lee YS, Han CH, Kang SH, et al. Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model. Int J Urol 2005 Apr; 12 (4): 383-9
16. Schaeffer AJ. Epidemiology and evaluation of chronic pelvic pain syndrome in men. Int J Antimicrob Agents 2008 Feb; 31 Suppl. 1: S108-11
17. Weidner W, Ludwig M. Diagnostic management of chronic prostatitis. Prostatitis: etiopathology, diagnosis and therapy. Berlin: Springer-Verlag, 1994: 158-74
18. Weidner W, Schiefer HG. Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin. Infection 1991; 19 Suppl. 3: S165-6
19. Potts J, Payne RE. Prostatitis: infection, neuromuscular disorder, or pain syndrome? Proper patient classification is key. Cleve Clin J Med 2007 May; 74 Suppl. 3: S63-71
20. Lee SW, Liong ML, Yuen KH, et al. Adverse impact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. Urology 2008 Jan; 71 (1): 79-84
21. Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment. Drugs Aging 2003; 20 (15): 1111-25
22. Propert KJ, McNaughton-Collins M, Leiby BE, et al. A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome: the National Institutes of Health Chronic Prostatitis Cohort study. J Urol 2006 Feb; 175 (2): 619-23; discussion 23
23. Walz J, Perrotte P, Hutterer G, et al. Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int 2007 Dec; 100 (6): 1307-11
24. Ku JH, Kim SW, Paick JS. Epidemiologic risk factors for chronic prostatitis. Int J Androl 2005 Dec; 28 (6): 317-27
25. Krieger JN, Lee SW, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents 2008 Feb; 31 Suppl. 1: S85-90
26. Wallner LP, Clemens JQ, Sarma AV. Prevalence of and risk factors for prostatitis in African American men: The Flint Men's Health Study. Prostate. Epub 2008 Sep 18
27. McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med 2000 Sep 5; 133 (5): 367-81
28. Hochreiter WW, Duncan JL, Schaeffer AJ. Evaluation of the bacterial flora of the prostate using a 16S rRNA gene based polymerase chain reaction. J Urol 2000 Jan; 163 (1): 127-30
29. Nadler RB, Collins MM, Propert KJ, et al. Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/ chronic pelvic pain syndrome. Urology 2006 Feb; 67 (2): 337-42
30. Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: are they related? Curr Urol Rep 2006 Jul; 7 (4): 329-34
31. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents 2008 Feb; 31 Suppl. 1: S112-6
32. Nadler RB. Bladder training biofeedback and pelvic floor myalgia. Urology 2002 Dec; 60 (6 Suppl.): 42-3; discussion 4
33. Nickel JC, Berger R, Pontari M. Changing paradigms for chronic pelvic pain: a report from the chronic pelvic pain/chronic prostatitis scientific workshop, October 19-21, 2005, Baltimore, MD. Rev Urol 2006; 8 (1): 28-35
34. Hochreiter WW, Nadler RB, Koch AE, et al. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 2000 Dec 20; 56 (6): 1025-9
35. Kaplan SA, Ikeguchi EF, Santarosa RP, et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996 Jun; 47 (6): 836-9
36. Hetrick DC, Ciol MA, Rothman I, et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III: a case-control study. J Urol 2003 Sep; 170 (3): 828-31
37. Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology 1997 Dec; 50 (6): 893-9
38. Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988 Nov; 140 (5): 1049-53
39. Kirby RS, Lowe D, Bultitude MI, et al. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982 Dec; 54 (6): 729-31
40. de la Rosette JJ, Ruijgrok MC, Jeuken JM, et al. Personality variables involved in chronic prostatitis. Urology 1993 Dec; 42 (6): 654-62
41. Pontari MA, McNaughton-Collins M, O'Leary MP, et al. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 2005 Sep; 96 (4): 559-65
42. Nickel JC, Shoskes D, Wang Y, et al. How does the premassage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/ chronic pelvic pain syndrome? J Urol 2006 Jul; 176 (1): 119-24
43. Meares EM, Stamey TA. Bacteriologic localization pattern in bacterial prostatitis and urethritis. Invest Urol 1968; 5: 492-518
44. Nickel JC. The pre and post massage test (PPMT): a simple screen for prostatitis. Tech Urol 1997 Spring; 3 (1): 38-43
45. Nickel J. Chronic prostatitis/chronic pelvic pain syndrome: a decade of change. AUA Update Series 2006; 25: 309-16
46. Nickel JC, Alexander RB, Schaeffer AJ, et al. Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. JUrol 2003 Sep; 170 (3): 818-22
47. Nadler RB, Rubenstein JN. Laparoscopic excision of a seminal vesicle for the chronic pelvic pain syndrome. J Urol 2001 Dec; 166 (6): 2293-4
48. Koulis H, Lam H. Prostatitis: a review of clinical management. US Pharmacist 2006; 31 (8): 107-16
49. Leskinen MJ, Kilponen A, Lukkarinen O, et al. Transurethral needle ablation for the treatment of chronic pelvic pain syndrome (category III prostatitis): a randomized, sham-controlled study. Urology 2002 Aug; 60 (2): 300-4
50. Kastner C, Hochreiter W, Huidobro C, et al. Cooled transurethral microwave thermotherapy for intractable chronic prostatitis: results of a pilot study after 1 year. Urology 2004 Dec; 64 (6): 1149-54
51. Cornel EB, van Haarst EP, Schaarsberg RW, et al. The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III. Eur Urol 2005 May; 47 (5): 607-11
52. Ye ZQ, Cai D, Lan RZ, et al. Biofeedback therapy for chronic pelvic pain syndrome. Asian J Androl 2003 Jun; 5 (2): 155-8
53. Clemens JQ, Nadler RB, Schaeffer AJ, et al. Biofeedback, pelvic floor re-education, and bladder training for male chronic pelvic pain syndrome. Urology 2000 Dec 20; 56 (6): 951-5
54. Schaeffer AJ, Darras FS. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J Urol 1990 Sep; 144 (3): 690-3
55. Pust RA, Ackenheil-Koppe HR, Gilbert P, et al. Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results. J Chemother 1989 Jul; 1 (4 Suppl.): 869-71
56. Drusano GL, Preston SL, Van Guilder M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000 Aug; 44 (8): 2046-51
57. Siegrist HH, Nepa MC, Jacquet A. Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study. J Antimicrob Chemother 1999 Jun; 43 Suppl. C: 51-4
58. Nickel JC, Downey J, Johnston B, et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/ chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol 2001 May; 165 (5): 1539-44
59. Nickel J, Zadeikis N, Spivey M. Clinical significance of antimicrobial therapy in chronic prostatitis associated with non-traditional uropathogens [abstract]. J Urol 2005; 173: S30
60. Nickel JC, Downey J, Clark J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003 Oct; 62 (4): 614-7
61. Alexander RB, Propert KJ, Schaeffer AJ, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/ chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004 Oct 19; 141 (8): 581-9
62. Nickel JC, Narayan P, McKay J, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004 Apr; 171 (4): 1594-7
63. Cheah PY, Liong ML, Yuen KH, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003 Feb; 169 (2): 592-6
64. Mehik A, Alas P, Nickel JC, et al. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 2003 Sep; 62 (3): 425-9
65. Evliyaoglu Y, Burgut R. Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo. Int Urol Nephrol 2002; 34 (3): 351-6
66. Mishra VC, Browne J, Emberton M. Role of alpha-blockers in type III prostatitis: a systematic review of the literature. J Urol 2007 Jan; 177 (1): 25-30
67. Lee SW, Liong ML, Yuen KH, et al. Chronic prostatitis/ chronic pelvic pain syndrome: role of alpha blocker therapy. Urol Int 2007; 78 (2): 97-105
68. Jeong CW, Lim DJ, Son H, et al. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urol Int 2008; 80 (2): 157-61
69. Ye ZQ, Lan RZ, Yang WM, et al. Tamsulosin treatment of chronic non-bacterial prostatitis. J Int Med Res 2008 Mar-Apr; 36 (2): 244-52
70. Goldmeier D, Madden P, McKenna M, et al. Treatment of category IIIA prostatitis with zafirlukast: a randomized controlled feasibility study. Int J STD AIDS 2005 Mar; 16 (3): 196-200
71. Nickel JC, Pontari M, Moon T, et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 2003 Apr; 169 (4): 1401-5
72. Tugcu V, Tasci AI, Fazlioglu A, et al. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category IIIB chronic pelvic pain syndrome (CPPS). Eur Urol 2007 Apr; 51 (4): 1113-7; discussion 8
73. Nickel JC, Downey J, Pontari MA, et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 2004 May; 93 (7): 991-5
74. Schaeffer A. Advances in the diagnosis and treatment of prostatitis. Urology 2002; 60 (6A): 1-44
75. Nickel JC, Forrest JB, Tomera K, et al. Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol 2005 Apr; 173 (4): 1252-5
76. Rugendorff EW, Weidner W, Ebeling L, et al. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993 Apr; 71 (4): 433-8
77. Egert S, Wolffram S, Bosy-Westphal A, et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 2008 Sep; 138 (9): 1615-21
78. Shoskes DA, Zeitlin SI, Shahed A, et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999 Dec; 54 (6): 960-3
79. Hilliard JJ, Krause HM, Bernstein JI, et al. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Adv Exp Med Biol 1995; 390: 59-69
80. Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004 Jan; 171 (1): 284-8
81. Nickel JC. Opioids for chronic prostatitis and interstitial cystitis: lessons learned from the 11th world congress on pain. Urology 2006 Oct; 68 (4): 697-701